[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100079193":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Wills Eye","OTHER",[8,12,14,17],{"label":9,"type":10,"description":11,"interventionNames":10},"Cross-Sectional Study",null,"Subjects will undergo a comprehensive ocular examination at every visit. Frequency of the visits is dictated by the treating physician, disregarding participation in the study. In glaucoma clinic patients are typically scheduled for visits every six months, and the frequency of visits varies according to clinical severity in the retina clinic. No additional research visits are required beyond the clinically dictated schedule.",{"label":13,"type":10,"description":11,"interventionNames":10},"Longitudinal Study",{"label":15,"type":10,"description":16,"interventionNames":10},"Reproducibility Study","Subjects willing to participate in the reproducibility arm of the project will undergo the same comprehensive ocular examination as in the longitudinal and cross-sectional study arms. However, OCT scanning will be repeated up to five times within a single visit. The participants will be requested to repeat the visual field and OCT scanning in up to 5 additional independent visits within a month to minimize the possibility that an actual change in ocular structures has occurred. Duration of each additional visit will be up to 45 minutes.",{"label":18,"type":10,"description":19,"interventionNames":10},"Alzheimer's Disease (AD) Sub-Study","Participants with AD or mild cognitive impairment (MCI) undergo the same comprehensive ocular examination as in the longitudinal and cross-sectional study arms.",[21],{"name":22,"affiliation":23,"role":24},"Joel S Schumann, MD","Wills Eye Hospital","STUDY_CHAIR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Taylor Harwood","CONTACT","215-928-3197","tharwood@willseye.org",{"name":32,"role":28,"phone":29,"phoneExt":10,"email":33},"Ronald Zambrano","rzambrano@willseye.org",[35],{"facility":23,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Philadelphia","Pennsylvania","19107","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-75.16362,39.95238,{"lat":46,"lon":45},[49,50,51,54],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},{"name":32,"role":28,"phone":29,"phoneExt":10,"email":33},{"name":52,"role":53,"phone":10,"phoneExt":10,"email":10},"Joel S Schuman, MD","PRINCIPAL_INVESTIGATOR",{"name":55,"role":56,"phone":10,"phoneExt":10,"email":10},"Gadi Wollstein, MD","SUB_INVESTIGATOR",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[60],{"name":61,"class":62},"National Eye Institute (NEI)","NIH","100079193","novel-glaucoma-diagnostics-100079193",false,"NCT00286637","Novel Glaucoma Diagnostics","Novel Diagnostics for Ocular Structure","Inclusion Criteria:\n\n* Ability to provide informed consent and to understand the study procedures\n* Healthy volunteers\n* Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and\u002For glaucoma or glaucoma suspects\n* (AD Sub-Study ONLY): Subjects diagnosed with AD or MCI.\n\nExclusion Criteria:\n\n* Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma.\n* Strabismus, nystagmus, or any condition that prevents fixation.\n* Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality\n* History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.",true,"ALL","18 Years",{"count":74,"type":75},5000,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases",[79,80],"Glaucoma","Macular Disease",[82,83,84,85,86,87,88,89,90,91],"OCT","CSLO","SLP","Perimetry","electrophysiology","glaucoma","macular degeneration","retinopathy","diabetes","macular hole","2024-08-13",{"date":94,"type":95},"2024-08-15","ACTUAL",{"date":97,"type":95},"2000-08-01",{"date":99,"type":75},"2029-07-31",{"name":5,"class":6},1]